All In Biotech

Drug Trial Radar · NCT00618436

Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention

Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit

Last checked: Nov 20, 2026Latest source record: Apr 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Aug 2007

Primary completion

Sep 2009

Study completion Sep 2009

Sponsor

Lead sponsor
University of CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Mayfield Clinic & Spine Institute
First posted
Feb 20, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To show that the use of intravenous levetiracetam(LEV;Keppra)for seizure prevention in patients in the Neuroscience Intensive Care Unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preventing clinical and sub-clinical seizure activity.

Conditions

  • Traumatic Brain Injury
  • Subarachnoid Hemorrhage

Interventions

  • LevetiracetamDrug

    Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.

  • PhenytoinDrug

    The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seizure IncidenceTime frame: Duration of study, up to 6 months after the injury

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Cincinnati Hospital

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.